BofA/Merrill Lynch downgraded ResMed (NYSE: RMD) from Buy to Neutral. Earlier ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Downgrades

Jefferies Drops Price Target After ResMed (RMD) Heart Failure Trial Fails May 14, 2015 10:19 AM ResMed (RMD) Announces SERVE-HF Missed Primary EndpointMay 13, 2015 6:14 AM ResMed Provides Update on Phase III SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy In Central Sleep Apnea and Chronic Heart FailureMay 13, 2015 3:00 AM